復宏漢霖(02696.HK)HLX79注射液聯合漢利康治療活動期腎小球腎炎 2期臨床研究於中國完成首例患者給藥
復宏漢霖(02696.HK)公布,近日一項HLX79注射液(人唾液酸(酉每)融合蛋白)(HLX79)聯合漢利康(利妥昔單抗注射液)治療活動期腎小球腎炎的2期臨床研究於中國境內完成首例患者給藥。
研究為一項雙盲、隨機對照、多中心的2期臨床試驗,旨在評估HLX79聯合漢利康對比安慰劑在活動期腎小球腎炎(狼瘡腎炎(LN)和膜性腎病(MN))患者中的有效性、安全性和耐受性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.